Skip Navigation LinksHome > November 1, 2005 - Volume 53 - Issue 7 > Diagnosis and Treatment Utilizing Natriuretic Peptides
Journal of Investigative Medicine:
doi: 10.2310/6650.2005.53707
EB2005 Symposium Introduction

Diagnosis and Treatment Utilizing Natriuretic Peptides

Free Access

One of the missions of the American Federation for Medical Research (AFMR) is to facilitate translational research. With that objective, AFMR is proud to continue to sponsor the “Bench to Bedside Symposia” at the annual Experimental Biology (EB) meeting. More details on how to apply for holding a symposium for future EB meetings are provided at

The symposium “Diagnosis and Treatment Utilizing Natriuretic Peptides,” sponsored by the AFMR, was held at the 2005 EB meeting in San Diego, California, on April 4, 2005. This symposium was cosponsored by Quest Diagnostics, Inc. The session's content is summarized in the four articles that follow, each authored by one of the speakers at the symposium. Dr. Adolfo J. deBold (Ottawa Heart Institute, Ottawa, ON), who discovered the first of the natriuretic peptides (ie, atrial natriuretic factor, also termed atrial natriuretic peptide), reviewed what regulates natriuretic peptide production by the heart. Dr. John Burnett Jr (Mayo Clinic, Rochester, MN) reviewed natriuretic peptides as treatment modalities of congestive heart failure. Dr. Walter H. Hörl (University of Vienna, Vienna, Austria) reviewed natriuretic peptides as treatment modalities of acute and chronic kidney disease and the effects of hemodialysis on the circulating levels of natriuretic peptides. Lastly, Dr. David Vesely (University of South Florida Cardiac Hormone Center, Tampa, FL) presented data on the basic science and potential clinical application of the newest property of some of the natriuretic peptides, that is, their potential as anticancer agents.

The following articles discuss the molecular biology, animal experiments, and human investigations that have led to one of the natriuretic peptides to be used clinically to treat congestive heart failure. Further, their potential to move from the bench and animal experiments to the bedside to treat renal failure and cancer is outlined for the reader.

David L. Vesely, MD, PhD, Symposium Chair

Abdulla K. Salahudeen, MD, AFMR Vice‐President for Meetings and Symposia

Cited By:

This article has been cited 9 time(s).

Experimental and Clinical Transplantation
Fasting Serum Long-Acting Natriuretic Peptide Correlates With the Ankle Brachial Index in Renal Transplant Recipients
Ho, GJ; Chen, YC; Yin, WY; Chang, YJ; Lee, MC; Hsu, BG
Experimental and Clinical Transplantation, 11(4): 303-309.
World Journal of Gastroenterology
Localization of ANP-synthesizing cells in rat stomach
Li, CH; Pan, LH; Li, CY; Zhu, CL; Xu, WX
World Journal of Gastroenterology, 12(): 5674-5679.

Journal of Urology
Atrial natriuretic peptide attenuates hypoxia induced chemoresistance in prostate cancer cells
Bell, EN; Tse, MY; Frederiksen, LJ; Gardhouse, A; Pang, SC; Graham, CH; Siemens, DR
Journal of Urology, 177(2): 751-756.
Journal of Endocrinology
3.3 ',5-triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy
Michienzi, S; Bucci, B; Falzacappa, CV; Patriarca, V; Stigliano, A; Panacchia, L; Brunetti, E; Toscano, V; Misiti, S
Journal of Endocrinology, 193(2): 209-223.
Cancer Research
Natriuretic peptide receptor A as a novel anticancer target
Kong, X; Wang, X; Xu, W; Behera, S; Hellermann, G; Kumar, A; Lockey, RF; Mohapatra, S; Mohapatra, SS
Cancer Research, 68(1): 249-256.
Diabetology & Metabolic Syndrome
Inverse association of long-acting natriuretic peptide with metabolic syndrome in congestive heart failure patients
Wang, JH; Lee, CJ; Hsieh, JC; Chen, YC; Hsu, BG
Diabetology & Metabolic Syndrome, 5(): -.
Archives of Medical Research
Low Serum Long-acting Natriuretic Peptide Level Correlates with Metabolic Syndrome in Hypertensive Patients: A Cross-sectional Study
Hsieh, JC; Wang, JH; Lee, CJ; Chen, YC; Liou, HH; Hsube, BG
Archives of Medical Research, 44(3): 215-220.
Oncology Letters
Atrial natriuretic peptide modulates the proliferation of human gastric cancer cells via KCNQ1 expression
Zhang, J; Zhao, ZL; Zu, C; Hu, HJ; Shen, H; Zhang, MX; Wang, JS
Oncology Letters, 6(2): 407-414.
Journal of Investigative Medicine
Designer Natriuretic Peptides
Lee, CY; Lieu, H; Burnett, JC
Journal of Investigative Medicine, 57(1): 18-21.
PDF (438) | CrossRef
Back to Top | Article Outline

© 2005 American Federation for Medical Research